Al-OlaAAbdallahMD

PubMed

• Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
  William Wesson, Nausheen Ahmed, Aliya Rashid, Carine Tabak, Emerson Logan, Jose Marchena-Burgos, Maggie Nelson, James A Davis, Mary McGann, Leyla Shune, Marc Hoffmann,...> ;European Journal of Haematology. 2024 Apr 1
• Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
  Mansour, R., Davis, J., Minchak, M., Atallah, R., Logan, E., Tabak, C., Rashid, A., Ahmed, N., Dima, D., Goel, U., Abdallah, A., Hashmi, H.> ;European Journal of Haematology. 2024 Feb 21
• Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Mu...
  Gagelmann, N., Dima, D., Merz, M., Hashmi, H., Ahmed, N., Tovar, N., Oliver-Caldés, A., Stölzel, F., Rathje, K., Fischer, L., Born, P., Schäfer, L., Albici, A., Schub,...> ;Journal of Clinical Oncology. 2024 Feb 15
• Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world m...
  Raza, S., Danai Dima, Aliya Rashid, James A Davis, Leyla Shune, Al-Ola Abdallah, Hong Li, Shaun DeJarnette, Jack Khouri, Louis Williams, Hamza Hashmi, Shahzad Raza, Jo...> ;British Journal of Haematology. 2024 Apr 1
• 1 citations
  Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation.
  Amin, M., DeJarnette, S., Li, K., Mushtaq, M., Shahzad, M., Lutfi, F., Al-Ramahi, J., Ahmed, N., Bansal, R., Abdelhakim, H., Shune, L., Abdallah, A., Abhyankar, S., Mc...> ;Leukemia & Lymphoma. 2024 Apr 1
• Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation.
  Amin, M., Mushtaq, M., Joe S Al-Ramahi, Moazzam Shahzad, Andrea Nguyen, Kevin Li, Muhammad Kashif Amin, Nausheen Ahmed, Forat Lutfi, Shaun DeJarnette, Sibgha Gull Chau...> ;Bone Marrow Transplantation. 2024 Jan 1
• Exploring the High-Grade and Refractory Neurotoxicity of Teclistamab: An Underreported Entity.
  Nelson, M., Hamideh, J., Mahmoudjafari, Z., Lutfi, F., Abdallah, A., Nashatizadeh, M., Ahmed, N., Shune, L.> ;Cureus. 2023 Nov 1
• Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Mu...
  Aimaz Afrough, Shebli Atrash, Barry Paul, Evguenia Ouchveridze, Nausheen Ahmed, Zahra Mahmoudjafari, Anam Bashir, Omar Alkharabsheh, Hamza Hashmi, Al-Ola Abdallah> ;Cancers. 2023 Oct 9
• 2 citations
  Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
  Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N Libby, Maria Chau...> ;Cancer. 2023 Dec 1
• 'A stitch in time saves nine': early stem cell transplant continues to improve outcomes in patients with newly diagnosed multiple myeloma.
  Hamza Hashmi, James A Davis, Al-Ola Abdallah> ;Expert Review of Hematology. 2023 Jun 23
• Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy.
  Shebli Atrash, Aytaj Mammadzadeh, Fulei Peng, Omar Alkharabsheh, Aimaz Afrough, Wei Cui, Zahra Mahmoudjafari, Al-Ola Abdallah, Hamza Hashmi> ;Cancers. 2023 May 24
• The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma.
  Syed Maaz Tariq, Al-Ola Abdallah, Aaron Goodman, Douglas Sborov, Ghulam Rehman Mohyuddin, Alec Britt> ;Clinical Hematology International. 2023 Jun 1
• 1 citations
  Dawn of Hope for Improved Access to BCMA Therapy: Chimeric Antigen Receptor T Cell and Bispecific Products.
  Nausheen Ahmed, William Wesson, Al-Ola Abdallah> ;Transplantation and Cellular Therapy. 2023 Jul 1
• 2 citations
  Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
  Alexander Lesokhin, Richard LeBlanc, Meletios A Dimopoulos, Marcelo Capra, Carmelo Carlo-Stella, Lionel Karlin, Jean-Francois Castilloux, Peter Forsberg, Gurdeep Parma...> ;Cancer Medicine. 2023 May 1
• 3 citations
  Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
  Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron G...> ;British Journal of Haematology. 2023 Mar 1
• 3 citations
  Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma.
  Al-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed, Wei Cui, Leyla Shune, Joseph McGuirk, Meera Mohan, Ghulam Rehman Mohyuddin, Aimaz Afrough, Omar Alkharabsheh, She...> ;European Journal of Haematology. 2023 Jun 1
• Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexametha...
  Omar Alkharabsheh, Polina Bellman, Zahra Mahmoudjafari, Wei Cui, Shebli Atrash, Barry Paul, Hamza Hashmi, Leyla Shune, Nausheen Ahmed, Al-Ola Abdallah> ;Journal of Hematology. 2023 Feb 1
• 1 citations
  Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to ...
  Hamza Hashmi, Shebli Atrash, Jayanshu Jain, Ghena Khasawneh, Meera Mohan, Zahra Mahmoudjafari, Wei Cui, Joseph McGuirk, Leyla Shune, Nausheen Ahmed, Al-Ola Abdallah> ;Transplantation and Cellular Therapy. 2023 Apr 1
• 2 citations
  Retrospective Review of Outcomes of Multiple Myeloma (MM) Patients With COVID-19 Infection (Two-Center Study).
  Hamid Ehsan, Alec Britt, Peter M Voorhees, Barry Paul, Manisha Bhutani, Cindy Varga, Zane Chiad, Brittany K Ragon, Al-Ola A Abdallah, Nausheen Ahmed, Shebli Atrash> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Apr 1
• Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.
  Nicole Birrer, William Wesson, Edward R Scheffer Cliff, Aaron M Goodman, Al-Ola Abdallah, Rajshekhar Chakraborty, Vinay Prasad, Ghulam Rehman Mohyuddin, Oliver Van Oek...> ;Blood Cancer Journal. 2022 Nov 15
• 2 citations
  Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma.
  Geoffrey McInturf, Kimberly Younger, Courtney Sanchez, Charles Walde, Al-Ola Abdallah, Nausheen Ahmed, Leyla Shune, Douglas W Sborov, Amandeep Godara, Brian McClune, C...> ;European Journal of Haematology. 2022 Nov 1
• 24 citations
  Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/...
  Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G Richardson, Thierry Facon, Katja Weisel, Jeremy T Larsen, Monique C Minnema, Al-Ola A...> ;The Lancet. Haematology. 2022 Nov 1
• 10 citations
  Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma.
  Tahani Atieh, Shebli Atrash, Nausheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Susana Hajjar, Zahra Mahmoudjafari, Julie Quick, Anne Wishna, Justin Riffel, Joseph McG...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Dec 1
• 3 citations
  Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acu...
  Linlin Gao, Stephen Hyter, Da Zhang, Sarah Kelting, Janet Woodroof, Al-Ola Abdallah, Abdulraheem Yacoub, Joseph McGuirk, Haitham Abdelhakim, Andrew K Godwin, Wei Cui> ;International Journal of Laboratory Hematology. 2022 Aug 1
• 4 citations
  Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination.
  Al-Ola Abdallah, Zahra Mahmoudjafari, Tahani Atieh, Nausheen Ahmed, Wei Cui, Leyla Shune, Meera Mohan, Joseph McGuirk, Cassie Remker, Margaret Foss, Ellie Karloff, Hea...> ;European Journal of Haematology. 2022 Nov 1
• Join now to see all

Lectures

• SGNBCMA-001: A phase 1 study of SEA‑BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma. 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019